Renin-angiotensin-system-acting agents - for COVID 19 hospitalized   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.97 [0.38, 2.50]< 10%1 study (1/-)52.5 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.97 [0.38, 2.50]< 10%1 study (1/-)52.5 %some concernnot evaluable moderatecrucial-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 95,94,90,91 95